Which has preferable earnings and valuation, CNTX or TNYA?

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A

Is CNTX or TNYA more profitable?

Context Therapeutics' return on equity of -82.06% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Tenaya Therapeutics N/A -83.75% -66.53%

Does the media favor CNTX or TNYA?

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Context Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.44 beat Context Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, OKUR or CNTX?

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is OKUR or CNTX more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Context Therapeutics N/A -82.06% -72.74%

Does the media prefer OKUR or CNTX?

In the previous week, OnKure Therapeutics had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for OnKure Therapeutics and 1 mentions for Context Therapeutics. OnKure Therapeutics' average media sentiment score of 0.00 equaled Context Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CNTX or CNTB more profitable?

Context Therapeutics' return on equity of -82.06% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Connect Biopharma N/A -165.41% -121.58%

Does the media refer more to CNTX or CNTB?

In the previous week, Connect Biopharma had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Connect Biopharma and 1 mentions for Context Therapeutics. Connect Biopharma's average media sentiment score of 0.13 beat Context Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INDP or CNTX?

Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,598.81%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has stronger earnings and valuation, INDP or CNTX?

Context Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is INDP or CNTX more profitable?

Context Therapeutics' return on equity of -82.06% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -302.89% -203.49% Context Therapeutics N/A -82.06% -72.74%

Does the media prefer INDP or CNTX?

In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 1 articles in the media. Indaptus Therapeutics' average media sentiment score of 1.38 beat Context Therapeutics' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CNTX or IMDX?

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Context Therapeutics (CNTX) Competitors

$0.36 +0.00 (+0.08%)

As of 09/3/2026 04:00 PM Eastern

Compare

CNTX vs. TNYA, OKUR, CNTB, INDP, and IMDX

Should you buy Context Therapeutics stock or one of its competitors? Context Therapeutics's main competitors and comparable companies include Tenaya Therapeutics (TNYA), OnKure Therapeutics (OKUR), Connect Biopharma (CNTB), Indaptus Therapeutics (INDP), and Oncocyte (IMDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Context Therapeutics compare to Tenaya Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Context Therapeutics currently has a consensus price target of $6.17, indicating a potential upside of 1,598.81%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 475.29%. Given Context Therapeutics' higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Tenaya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Context Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market.

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Context Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.44 beat Context Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics' return on equity of -82.06% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Summary

Context Therapeutics and Tenaya Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

OnKure Therapeutics' return on equity of -49.01% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Context Therapeutics	N/A	-82.06%	-72.74%

OnKure Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, OnKure Therapeutics had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for OnKure Therapeutics and 1 mentions for Context Therapeutics. OnKure Therapeutics' average media sentiment score of 0.00 equaled Context Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OnKure Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 391.57%. Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 1,598.81%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Summary

Context Therapeutics beats OnKure Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Context Therapeutics compare to Connect Biopharma?

Context Therapeutics (NASDAQ:CNTX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Context Therapeutics currently has a consensus price target of $6.17, suggesting a potential upside of 1,598.81%. Connect Biopharma has a consensus price target of $7.43, suggesting a potential upside of 284.90%. Given Context Therapeutics' higher possible upside, equities research analysts plainly believe Context Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Connect Biopharma had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Connect Biopharma and 1 mentions for Context Therapeutics. Connect Biopharma's average media sentiment score of 0.13 beat Context Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics' return on equity of -82.06% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Connect Biopharma	N/A	-165.41%	-121.58%

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Context Therapeutics has higher earnings, but lower revenue than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Connect Biopharma	$60K	2,025.54	-$55.48M	-$1.19	N/A

Context Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market.

Summary

Context Therapeutics beats Connect Biopharma on 8 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Context Therapeutics' return on equity of -82.06% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-302.89%	-203.49%
Context Therapeutics	N/A	-82.06%	-72.74%

Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,598.81%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Context Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 1 articles in the media. Indaptus Therapeutics' average media sentiment score of 1.38 beat Context Therapeutics' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indaptus Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Summary

Context Therapeutics beats Indaptus Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Context Therapeutics compare to Oncocyte?

Context Therapeutics (NASDAQ:CNTX) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 1,598.81%. Oncocyte has a consensus target price of $10.50, suggesting a potential upside of 154.85%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Context Therapeutics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Context Therapeutics has higher earnings, but lower revenue than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Oncocyte	$4.05M	33.29	-$50.22M	-$1.49	N/A

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Context Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Oncocyte	-2,955.63%	N/A	-107.52%

Context Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Summary

Context Therapeutics beats Oncocyte on 9 of the 13 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33.33M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.76	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.86	16.29	12.89	6.14
Net Income	-$36.12M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-5.39%	0.34%	0.60%	-0.27%
1 Month Performance	-41.62%	8.52%	5.73%	0.68%
1 Year Performance	-56.16%	52.66%	25.35%	14.84%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	2.4763 of 5 stars	$0.36 +0.1%	$6.17 +1,598.8%	-56.9%	$33.33M	N/A	N/A	7	Gap Up
TNYA Tenaya Therapeutics	2.1504 of 5 stars	$0.70 +4.0%	$4.00 +469.8%	-41.1%	$157.41M	$1.34M	N/A	110
OKUR OnKure Therapeutics	2.8594 of 5 stars	$3.88 -0.4%	$17.50 +351.6%	+25.8%	$156.55M	N/A	N/A	N/A	News Coverage
CNTB Connect Biopharma	3.3988 of 5 stars	$2.42 +5.0%	$7.43 +207.6%	-3.0%	$152.07M	$60K	N/A	110	Gap Up
INDP Indaptus Therapeutics	0.6105 of 5 stars	$1.10 -5.6%	N/A	-78.5%	$145.90M	N/A	N/A	6	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. TNYA, OKUR, CNTB, INDP, and IMDX

How does Context Therapeutics compare to Tenaya Therapeutics?

Summary

How does Context Therapeutics compare to OnKure Therapeutics?

Summary

How does Context Therapeutics compare to Connect Biopharma?

Summary

How does Context Therapeutics compare to Indaptus Therapeutics?

Summary

How does Context Therapeutics compare to Oncocyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. TNYA, OKUR, CNTB, INDP, and IMDX

How does Context Therapeutics compare to Tenaya Therapeutics?

Do analysts recommend CNTX or TNYA?

Which has more risk & volatility, CNTX or TNYA?

Which has preferable earnings and valuation, CNTX or TNYA?

Do insiders and institutionals have more ownership in CNTX or TNYA?

Does the media favor CNTX or TNYA?

Is CNTX or TNYA more profitable?

Summary

How does Context Therapeutics compare to OnKure Therapeutics?

Is OKUR or CNTX more profitable?

Which has more risk and volatility, OKUR or CNTX?

Do insiders & institutionals believe in OKUR or CNTX?

Does the media prefer OKUR or CNTX?

Do analysts recommend OKUR or CNTX?

Which has higher earnings and valuation, OKUR or CNTX?

Summary

How does Context Therapeutics compare to Connect Biopharma?

Do analysts rate CNTX or CNTB?

Does the media refer more to CNTX or CNTB?

Is CNTX or CNTB more profitable?

Do insiders and institutionals believe in CNTX or CNTB?

Which has preferable valuation & earnings, CNTX or CNTB?

Which has more volatility & risk, CNTX or CNTB?

Summary

How does Context Therapeutics compare to Indaptus Therapeutics?

Is INDP or CNTX more profitable?

Do analysts rate INDP or CNTX?

Do institutionals & insiders believe in INDP or CNTX?

Which has stronger earnings and valuation, INDP or CNTX?

Does the media prefer INDP or CNTX?

Which has more volatility and risk, INDP or CNTX?

Summary

How does Context Therapeutics compare to Oncocyte?

Does the media favor CNTX or IMDX?

Do analysts rate CNTX or IMDX?

Which has preferable earnings and valuation, CNTX or IMDX?

Do institutionals and insiders hold more shares of CNTX or IMDX?

Is CNTX or IMDX more profitable?

Which has more volatility & risk, CNTX or IMDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools